AML
News
Tumor suppressor promotes FLT3-ITD AML
New research indicates that RUNX1, a known tumor suppressor, actually cooperates with internal tandem duplications in the FLT3 receptor tyrosine...
News
Model illustrates progression to MDS, AML
Researchers say they have created a model that shows the step-by-step progression from normal blood cells to acute myeloid leukemia (AML). The...
News
Site of care may impact survival for AYAs with ALL, AML
Receiving treatment at specialized cancer centers may improve survival for adolescents and young adults (AYAs) with acute leukemia, according to a...
News
Styrene exposure linked to myeloid leukemia, HL
A new study links styrene—a chemical used in the manufacture of plastics, rubber, and resins—to certain cancers. The research showed that,...
News
Group identifies ‘essential’ genes in AML
CRISPR-based genetic screens have revealed essential genes—those required for cellular proliferation and survival—in 14 acute myeloid leukemia (...
News
Computer predicts remission, relapse in AML
Researchers say they have developed the first computer machine-learning model to accurately predict which patients diagnosed with acute myeloid...
News
Azathioprine may increase risk of MDS, AML
Results of a large, retrospective study suggest that taking azathioprine, a drug commonly used to treat autoimmune disease, may increase a person’...
News
Company reports third death in SL-401 trial
Stemline Therapeutics, Inc.
News
Targeting disease stem cells in AML, MDS
The cell surface molecule CD99 occurs more frequently than normal on stem cells responsible for acute myeloid leukemia (AML) and myelodysplastic...
From the Journals
AML leads percent gains in 5-year survival among leukemias
For 2008-2013, the 5-year relative survival rate for all leukemia was 60.1%, compared with 10% in 1950-1954.
News
New recommendations for managing adult AML
The European LeukemiaNet (ELN) has released updated recommendations for the diagnosis and treatment of acute myeloid leukemia (AML) in adults.